Cinclus Pharma Holding AB: Promising Growth Potential with Linaprazan Glurate and Strategic Partnerships

Analyst Oscar Haffen Lamm of Stifel Nicolaus maintained a Buy rating on Cinclus Pharma Holding AB, with a price target of SEK60.00.

Oscar Haffen Lamm has given his Buy rating due to a combination of factors that highlight Cinclus Pharma Holding AB’s promising future. One of the primary reasons is the initiation of their first Phase 3 trial, which is designed to demonstrate superiority in healing over current proton pump inhibitors (PPIs). This trial aims to establish Linaprazan glurate’s (LG) effectiveness, particularly for severe eGERD patients, and could lead to significant differentiation in the market if successful. The management’s confidence in the trial’s progress and the potential for superior symptom relief, especially at night, further supports this positive outlook.
Additionally, the strong launch of vonoprazan in the US market underscores the unmet need for new drug classes with superior acid control, which LG aims to fulfill. The recent €220 million deal with Zentiva for European commercial rights also provides robust external validation of LG’s market potential. This agreement not only affirms LG’s best-in-class profile but also highlights its strong pricing potential in Europe. These factors collectively contribute to the high confidence in Cinclus Pharma’s growth prospects, justifying the Buy rating.